Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 9/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | FPR1 | P21462 | 1/20 | 0.43 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | GLP1R | P43220 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5534158 | 0.84 | GPBAR1 (0.49) | TACR1ADRB2FPR1GPR183APLNR | |
| SCHEMBL5527548 | 0.83 | ADRB2 (0.46) | TACR1ADRB2FPR1GPR183APLNR | |
| SCHEMBL6093341 | 0.82 | GPBAR1 (0.61) | TACR1ADRB2FPR1GPR183APLNR | |
| SCHEMBL6093417 | 0.82 | TACR1 (0.45) | TACR1ADRB2FPR1GPR183APLNR | |
| SCHEMBL6093277 | 0.82 | GPBAR1 (0.49) | TACR1ADRB2FPR1GPR183APLNR | |
| SCHEMBL5531984 | 0.82 | ADRB2 (0.49) | TACR1ADRB2FPR1GPR183APLNR | |
| SCHEMBL5532435 | 0.80 | GPBAR1 (0.47) | TACR1ADRB2FPR1GPR183APLNR | |
| SCHEMBL6989544 | 0.78 | GPBAR1 (0.50) | TACR1ADRB2FPR1GPR183APLNR | |
| SCHEMBL6794955 | 0.77 | TACR1 (0.49) | TACR1ADRB2FPR1GPR183APLNR | |
| SCHEMBL6788440 | 0.76 | TACR1 (0.51) | TACR1ADRB2FPR1GPR183APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1489083-B1 | FUSED BICYCLIC PYRIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | KYORIN SEIYAKU KK (JP) | 2007-06-06 | — | — | EP | disclosed |
| EP-1489083-B1 | FUSED BICYCLIC PYRIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | KYORIN SEIYAKU KK (JP) | 2007-06-06 | — | — | EP | disclosed |
| US-7030107-B2 | nitrogen compounds such as 5-[3,5-bis(trifluoromethyl)benzyl]-6-oxo-7-phenyl-9-[4-(pyrrolidine-1-yl)piperidine-1-yl]-2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocine, used as neurokinin inhibitors for prophylaxis of urogenital disorders; side effect reduction | KYORIN PHARMACEUTICAL.CO., LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-7026309-B2 | Fused bicyclic pyridine derivative as tachykinin receptor antagonist | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-04-11 | — | — | US | disclosed |
| US-20050107375-A1 | Fused bicyclic pyridine derivatives as tachykinin receptor antagonists | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-05-19 | — | — | US | disclosed |
| US-20050101591-A1 | Fused bicyclic pyridine derivative as tachykinin receptor antagonist | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1489083-A1 | FUSED BICYCLIC PYRIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-12-22 | — | — | EP | disclosed |
| EP-1457493-A1 | FUSED BICYCLIC PYRIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107375-A1 | Fused bicyclic pyridine derivatives as tachykinin receptor antagonists | BDKRB1, BDKRB2, TACR1 | TACR1 3/4885ADRB2 247/4885FPR1 250/4885 |
| US-20050101591-A1 | Fused bicyclic pyridine derivative as tachykinin receptor antagonist | BDKRB1, BDKRB2, NPY1R | TACR1 4/4885ADRB2 150/4885FPR1 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.